Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
225 studies found for:    folate receptor
Show Display Options
Rank Status Study
1 Unknown  The Development of Human Immunologic Assays Specific to Folate Receptor Antigen
Condition: Ovarian Cancer
Intervention: Procedure: venous puncture
2 Completed Measurement of the Folate Receptor in Blood
Condition: Healthy
Intervention:
3 Recruiting Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours
Condition: Human Cancers
Intervention: Drug: MOv18 IgE
4 Completed
Has Results
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Conditions: Epilepsy;   Psychiatric or Mood Diseases or Conditions
Intervention: Other: No intervention
5 Recruiting Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Conditions: Adnexal Mass;   Borderline Ovarian Epithelial Tumor;   Ovarian Clear Cell Tumor;   Ovarian Endometrioid Tumor;   Ovarian Neoplasm;   Ovarian Serous Tumor;   Recurrent Ovarian Carcinoma
Interventions: Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Valproic Acid
6 Recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRα vaccine;   Drug: Cyclophosphamide;   Biological: High dose FRα vaccine
7 Completed FR in Stored Plasma
Condition: Ovarian Cancer
Intervention:
8 Completed Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Technetium Tc 99m EC20
9 Recruiting TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: TPIV200;   Biological: Durvalumab
10 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Tumor;   Fallopian Tube Mucinous Neoplasm;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
11 Not yet recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Biological: FRα peptide plus Adjuvant (GM-CSF);   Drug: Adjuvant (GM-CSF) Alone
12 Not yet recruiting OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Conditions: Lung Neoplasms;   Lung Cancer
Intervention: Drug: OTL38 for Injection
13 Completed Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: OTL38
14 Recruiting A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Condition: Patients Presenting With Suspected Malignancies of the Pituitary Gland
Interventions: Drug: OTL0038;   Drug: Benadryl;   Device: intraoperative imaging
15 Active, not recruiting Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Breast Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine
16 Recruiting PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Ovarian Cancer
Interventions: Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Topotecan
17 Completed Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
18 Completed A Study of MORAb-003 in Patients With Solid Tumor
Condition: Patients With a Folate-receptor Alpha Expressing Solid Tumor Who Are Not Responsive or Resistant to Standard Therapy and Have no Other Appropriate Treatment.
Intervention: Drug: MORAb-003
19 Recruiting Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer
Interventions: Drug: IMGN853;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Pembrolizumab
20 Terminated
Has Results
A Folinic Acid Intervention for Autism Spectrum Disorders
Conditions: Autism Spectrum Disorder;   Autistic Disorder;   Autism;   Asperger's Syndrome;   Pervasive Development Disorders
Interventions: Drug: Folinic Acid and placebo;   Drug: Folinic Acid

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.